查看購物車
  • Simplified Chinese
  • English
  • Japanese
急性缺血性腦中風市場 - 全球及區域分析：按療法和區域 - 分析與預測（2025-2035 年）
市場調查報告書
商品編碼
1729049

急性缺血性腦中風市場 - 全球及區域分析：按療法和區域 - 分析與預測（2025-2035 年）

Acute Ischemic Stroke Market - A Global and Regional Analysis: Focus on Therapeutics, and Regional Analysis - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

當供應大腦的血管被血栓阻塞時，就會發生急性缺血性腦中風，導致神經功能突然喪失。

這種阻塞會導致腦組織缺乏所需的氧氣和營養，從而導致細胞死亡並可能造成長期損害。

全球急性缺血性腦中風市場的主要促進因素之一是文明病的盛行率不斷上升。高血壓、糖尿病和肥胖等文明病會增加缺血性中風的風險。這導致對藥物和治療方法的需求增加。

儘管成長軌跡良好，但仍有若干挑戰影響全球急性缺血性腦中風市場。主要挑戰之一是在資源匱乏的環境中難以獲得先進的醫療服務。然而，雖然 tPA 和血栓切除術等先進療法正在改善治療效果，但許多地區缺乏提供這些治療所需的基礎設施。這導致診斷和治療的延遲，從而導致中風相關的殘疾和死亡率顯著增加。

全球急性缺血性腦中風市場也面臨治療費用上漲的問題。然而，機械血栓切除術、tPA 和中風後復健等最先進治療的費用對於患者和醫療保健系統來說可能過高，尤其是在發展中地區。

每家公司都透過開發標靶治療在推動缺血性中風治療領域發展方面發揮關鍵作用。兩家公司正在進行的研究和合作對於改善患者的治療效果和擴大市場的治療選擇至關重要。

全球急性缺血性腦中風市場的競爭格局多種多樣，不同地區的眾多公司提供各種各樣的產品。隨著需求的不斷成長，尤其是在亞太等新興市場，預計區域參與企業和本地製造商將在市場成長中發揮關鍵作用。隨著消費者偏好轉向更謹慎、舒適和更實惠的治療方法，急性缺血性腦中風市場預計將繼續發展，為成熟公司和新興企業創造新的機會。

總之，在醫療保健投資和研究不斷增加的推動下，全球急性缺血性腦中風市場預計將持續成長。產品技術的不斷進步和治療選擇的不斷擴大將繼續塑造市場的未來。隨著急性缺血性腦中風市場需求的不斷成長，全球和區域參與者都有望在滿足個人和醫療保健系統的需求方面發揮關鍵作用。

本報告研究了全球急性缺血性腦中風市場，並概述了市場以及治療劑、地區和公司概況的趨勢。

目錄

執行摘要

第1章全球急性缺血性腦中風市場：產業展望

  • 概述
  • 急性缺血性腦中風的監管現狀
  • 急性缺血性腦中風市場及流行病學分析
  • 急性缺血性腦中風市場及專利模式
  • 急性缺血性腦中風市場和臨床試驗現狀
  • 主要趨勢
  • 市場動態

第 2 章。急性缺血性腦中風市場（按治療劑，百萬美元，2023-2035 年）

  • 溶栓治療
  • 抗血小板治療
  • 抗高血壓治療
  • 抗凝血劑

第 3 章。按地區分類的急性缺血性腦中風市場（百萬美元，2023-2035 年）

  • 北美洲
  • 歐洲
  • 亞太地區

第4章 競爭格局與公司概況

  • 競爭格局
    • 新服務
    • 合併與收購
    • 夥伴關係、合作和業務擴展
    • 資金籌措活動
    • 監管部門核准
  • 公司簡介
    • Acticor Biotech
    • Bristol-Myers Squibb
    • Genentech, Inc
    • Athersys|Healios KK
    • Biogen Inc
    • AbbVie
    • Revalesio Corporation
    • NoNO Inc.
    • Bayer
    • TrueBinding, Inc
    • Lumosa Therapeutics
    • Janssen Pharmaceutical
    • Silver Creek Pharmaceuticals

第5章調查方法

Product Code: BHL2880SA

Global Acute Ischemic Stroke Market, Analysis and Forecast: 2025-2035

An acute ischemic stroke occurs when a blood clot obstructs a blood vessel supplying blood to the brain, leading to a sudden loss of neurological function. This blockage deprives brain tissue of essential oxygen and nutrients, causing cell death and potential long-term disability.

One of the significant drivers of the global acute ischemic stroke market is the rising incidence of lifestyle disorders. The rising ages and lifestyle-related diseases such as hypertension, diabetes, and obesity which leads to increases the risk of ischemic stroke. This results in increasing demand of drug or therapies during the treatment.

Despite the positive growth trajectory, several challenges continue to impact the global acute ischemic stroke market. One of the primary challenges is limited access to advanced care in low-resource settings. However, the advanced treatments like tPA and thrombectomy have improved outcomes, many regions lack the necessary infrastructure to deliver these therapies. This results in underdiagnosis and delayed treatments, significantly increasing stroke-related disability and mortality.

The global acute ischemic stroke market is also facing high cost of treatment. However, the cost of cutting-edge treatments like mechanical thrombectomy, tPA, and post-stroke rehabilitation can be prohibitive for patients and healthcare systems, particularly in developing regions.

The companies play pivotal roles in advancing the treatment landscape for ischemic stroke through the development of targeted therapies. Their ongoing research and collaborations are essential in improving patient outcomes and expanding therapeutic options in this market.

The competitive landscape of the global acute ischemic stroke market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific. As consumer preferences shift towards more discreet, comfortable, and affordable therapies, the acute ischemic stroke market will continue to evolve, fostering new opportunities for both established and emerging companies.

Market Segmentation:

Segmentation 1: by Therapeutics

  • Thrombolytic Therapies
  • Antiplatelet Therapies
  • Antihypertensive Therapies
  • Anticoagulants

Segmentation 2: by Region

  • North America
  • Europe
  • Asia-Pacific

In conclusion, the global acute ischemic stroke market is on track for continued growth, driven by the growing healthcare investments and research. The ongoing advancements in product technology and the expansion of care options will continue to shape the market's future. As demand for acute ischemic stroke market rises the therapies, both global and regional players will play a key role in meeting the needs of individuals and healthcare systems.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Key Questions Answered

Analysis and Forecast Note

1. Global Acute Ischemic Stroke Market: Industry Outlook

  • 1.1 Overview
  • 1.2 Regulatory Landscape of Acute Ischemic Stroke
  • 1.3 Acute Ischemic Stroke Market, Epidemiology Analysis
  • 1.4 Acute Ischemic Stroke Market, Patent Landscape
    • 1.4.1 By Country
    • 1.4.2 By Year
  • 1.5 Acute Ischemic Stroke Market, Clinical Trials Landscape
  • 1.6 Key Trends
  • 1.7 Market Dynamics
    • 1.7.1 Impact Analysis
    • 1.7.2 Market Drivers
    • 1.7.3 Market Restraints
    • 1.7.3 Market Opportunities

2. Global Acute Ischemic Stroke Market, By Therapeutics, $Million, 2023-2035

  • 2.1 Thrombolytic Therapies
  • 2.2 Antiplatelet Therapies
  • 2.3 Antihypertensive Therapies
  • 2.4 Anticoagulants

3. Global Acute Ischemic Stroke Market, by Region, $Million, 2023-2035

  • 3.1 North America
    • 3.1.1 Key Findings in North America
    • 3.1.2 Business Drivers
    • 3.1.3 Business Challenges
    • 3.1.4 Market Sizing and Forecast
      • 3.1.4.1 North America Acute Ischemic Stroke Market, By Country
        • 3.1.4.1.1 U.S.
  • 3.2 Europe
    • 3.2.1 Key Findings in Europe
    • 3.2.2 Business Drivers
    • 3.2.3 Business Challenges
    • 3.2.4 Market Sizing and Forecast
      • 3.2.4.1 Europe Acute Ischemic Stroke Market, By Country
        • 3.2.4.1.1 Germany
        • 3.2.4.1.2 U.K.
        • 3.2.4.1.3 France
        • 3.2.4.1.4 Italy
        • 3.2.4.1.5 Spain
  • 3.3 Asia-Pacific
    • 3.3.1 Key Findings in Asia-Pacific
    • 3.3.2 Business Drivers
    • 3.3.3 Business Challenges
    • 3.3.4 Market Sizing and Forecast
      • 3.3.4.1 Asia-Pacific Acute Ischemic Stroke Market, By Country
        • 3.3.4.1.1 Japan

4. Competitive Landscape and Company Profiles

  • 4.1 Competitive Landscape
    • 4.1.1 New Offerings
    • 4.1.2 Mergers and Acquisitions
    • 4.1.3 Partnerships, Alliances, and Business Expansion
    • 4.1.4 Funding Activities
    • 4.1.5 Regulatory Approvals
  • 4.2 Company Profile
    • 4.2.1 Acticor Biotech
      • 4.2.1.1 Overview
      • 4.2.1.2 Product Portfolio
      • 4.2.1.3 Target Customers
      • 4.2.1.4 Key Professionals
      • 4.2.1.5 Analyst View
    • 4.2.2 Bristol-Myers Squibb
      • 4.2.2.1 Overview
      • 4.2.2.2 Product Portfolio
      • 4.2.2.3 Target Customers
      • 4.2.2.4 Key Professionals
      • 4.2.2.5 Analyst View
    • 4.2.3 Genentech, Inc
      • 4.2.3.1 Overview
      • 4.2.3.2 Product Portfolio
      • 4.2.3.3 Target Customers
      • 4.2.3.4 Key Professionals
      • 4.2.3.5 Analyst View
    • 4.2.4 Athersys|Healios K.K.
      • 4.2.3.1 Overview
      • 4.2.3.2 Product Portfolio
      • 4.2.3.3 Target Customers
      • 4.2.3.4 Key Professionals
      • 4.2.3.5 Analyst View
    • 4.2.5 Biogen Inc
      • 4.2.5.1 Overview
      • 4.2.5.2 Product Portfolio
      • 4.2.5.3 Target Customers
      • 4.2.5.4 Key Professionals
      • 4.2.5.5 Analyst View
    • 4.2.6 AbbVie
      • 4.2.6.1 Overview
      • 4.2.6.2 Product Portfolio
      • 4.2.6.3 Target Customers
      • 4.2.6.4 Key Professionals
      • 4.2.6.5 Analyst View
    • 4.2.7 Revalesio Corporation
      • 4.2.7.1 Overview
      • 4.2.7.2 Product Portfolio
      • 4.2.7.3 Target Customers
      • 4.2.7.4 Key Professionals
      • 4.2.7.5 Analyst View
    • 4.2.8 NoNO Inc.
      • 4.2.8.1 Overview
      • 4.2.8.2 Product Portfolio
      • 4.2.8.3 Target Customers
      • 4.2.8.4 Key Professionals
      • 4.2.8.5 Analyst View
    • 4.2.9 Bayer
      • 4.2.9.1 Overview
      • 4.2.9.2 Product Portfolio
      • 4.2.9.3 Target Customers
      • 4.2.9.4 Key Professionals
      • 4.2.9.5 Analyst View
    • 4.2.10 TrueBinding, Inc
      • 4.2.10.1 Overview
      • 4.2.10.2 Product Portfolio
      • 4.2.10.3 Target Customers
      • 4.2.10.4 Key Professionals
      • 4.2.10.5 Analyst View
    • 4.2.11 Lumosa Therapeutics
      • 4.2.11.1 Overview
      • 4.2.11.2 Product Portfolio
      • 4.2.11.3 Target Customers
      • 4.2.11.4 Key Professionals
      • 4.2.11.5 Analyst View
    • 4.1.12 Janssen Pharmaceutical
      • 4.2.12.1 Overview
      • 4.2.12.2 Product Portfolio
      • 4.2.12.3 Target Customers
      • 4.2.12.4 Key Professionals
      • 4.2.12.5 Analyst View
    • 4.2.13 Silver Creek Pharmaceuticals
      • 4.2.13.1 Overview
      • 4.2.13.2 Product Portfolio
      • 4.2.13.3 Target Customers
      • 4.2.13.4 Key Professionals
      • 4.2.13.5 Analyst View

5. Research Methodology

List of Figures

  • Figure: Global Acute Ischemic Stroke Market (by Region), $Million, 2024 and 2035
  • Figure: Global Acute Ischemic Stroke Market Coverage
  • Figure: Global Acute Ischemic Stroke Market Key Trends, Impact Analysis, 2024-2035

List of Tables

  • Table: Global Acute Ischemic Stroke Market, Patent Analysis, January 2022-March 2025
  • Table: Global Acute Ischemic Stroke Market Dynamics, Impact Analysis
  • Table: Global Acute Ischemic Stroke Market (by Therapeutics), $Million, 2023-2035
  • Table: Global Acute Ischemic Stroke Market (by Region), $Million, 2023-2035